Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is a comprehensive provider of cancer diagnostic testing, with a strong position in the community channel and a wide range of tests offered. We believe that the company's base clinical services business will continue to deliver steady MSD% growth, driven by an increasing contribution from the faster growth NGS segment and potential upside from new test launches. Additionally, management's efforts to optimize and increase ASP, as well as expansion into flow cytometry for heme MRD, could drive margin and cash flow improvement. With a strong foothold in the market, favorable outlook for NGS growth, and attractive positioning trading at <2x EV/S, we have a positive outlook on NeoGenomics.

Bears say

NeoGenomics is currently facing challenges in terms of environmental, social, and corporate governance (ESG) performance, as the company's focus on providing oncology diagnostic testing and services may not align with changing regulations and trends in healthcare. Additionally, the company's materiality assessment process may need to be revised in order to accurately capture and respond to important ESG factors. These challenges, combined with the company's overly conservative revenue projections and expected decline in non-clinical revenue, contribute to a negative outlook on NeoGenomics's stock.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.